1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected

Q&A With AmerisourceBergen’s Biosimilar Commercialization Director Brian Biehn

 
• By Dave Wallace

Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.

Empty map uncharted territory
Humira is “uncharted territory” for US biosimilars • Source: Shutterstock

As senior director of biosimilar commercialization at AmerisourceBergen, Brian Biehn focuses on successfully executing commercialization opportunities for AmerisourceBergen while providing customers with choice, access, and savings.

And as the biosimilars market continues to expand in the US, Biehn partners with manufacturers in the pre-commercial, launch, and post-launch phases to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products